Anastasopoulou Amalia, Diamantopoulos Panagiotis T, Kouzis Panagiotis, Saridaki Maria, Sideris Konstantinos, Samarkos Michael, Gogas Helen
First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Cancers (Basel). 2023 Dec 24;16(1):96. doi: 10.3390/cancers16010096.
We conducted a single-center, non-interventional retrospective study of melanoma patients with COVID-19 (1 March 2020 until 17 March 2023). The cohort was further divided into three groups according to the periods of SARS-CoV-2 variant dominance in Greece. We recorded demographics, comorbidities, vaccination data, cancer diagnosis/stage, types of systemic melanoma treatments, date of COVID-19 diagnosis and survival. We identified 121 patients. The vast majority (87.6%) had advanced disease (stages III or IV). A total of 80.1% of the patients were receiving immune checkpoint inhibitor-based therapies, 92.5% had asymptomatic/mild COVID-19 and 7.4% had moderate/severe/critical disease, while 83.5% contracted COVID-19 during the third period of the pandemic. Sixteen patients (13.2%) were hospitalized for COVID-19 with a median length of stay of 12 days (range: 1-55 days). Advanced age, heart failure, number of comorbidities (≤1 vs. >1), vaccination status and the time period of the infection correlated with more severe COVID-19, whereas only heart failure and time period were independently correlated with severity. The 30-day mortality rate after COVID-19 was 4.2%. With a median follow-up of 340 days post-COVID-19, 17.4% of patients were deceased. In this cohort of melanoma patients with COVID-19, the 30-day mortality rate was low. There was no association between melanoma stage, treatment receipt and type of treatment with COVID-19 severity.
我们对2020年3月1日至2023年3月17日期间感染新冠病毒的黑色素瘤患者进行了一项单中心、非干预性回顾性研究。根据希腊SARS-CoV-2变异株占主导地位的时期，该队列进一步分为三组。我们记录了人口统计学信息、合并症、疫苗接种数据、癌症诊断/分期、系统性黑色素瘤治疗类型、新冠病毒诊断日期和生存情况。我们确定了121例患者。绝大多数（87.6%）患有晚期疾病（III期或IV期）。共有80.1%的患者接受基于免疫检查点抑制剂的治疗，92.5%的患者患有无症状/轻度新冠病毒感染，7.4%的患者患有中度/重度/危重症，而83.5%的患者在疫情的第三个时期感染了新冠病毒。16例患者（13.2%）因新冠病毒感染住院，中位住院时间为12天（范围：1-55天）。高龄、心力衰竭、合并症数量（≤1与>1）、疫苗接种状况和感染时间与更严重的新冠病毒感染相关，而只有心力衰竭和感染时间与严重程度独立相关。新冠病毒感染后的30天死亡率为4.2%。在新冠病毒感染后中位随访340天，17.4%的患者死亡。在这个感染新冠病毒的黑色素瘤患者队列中，30天死亡率较低。黑色素瘤分期、治疗接受情况和治疗类型与新冠病毒感染严重程度之间没有关联。
